CD8A and neoplasm: siRNA against TGF-b decreased Treg level and enhanced DC-based cancer vaccine in mice with “cold” melanoma tumor (124), and siRNA targeting Interleukin-10 receptor alpha (IL-10Ra) initiated tumor-specific CD8+ T cell immune responses (125).